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Background: Botulinum toxins are considered first-line therapy for treatment of cervical dystonia (CD) and must be
injected on a repeat basis. Understanding the duration of clinical benefit of botulinum toxins and its impact on
health care utilization are thus important in the contemporary environment. However, there is currently no overall
consensus on the duration of effect of onabotulinumtoxinA in the treatment of CD. We performed a systematic
review and meta-analysis to identify the duration of effect of onabotulinumtoxinA in CD and investigate factors that
may influence it.
Methods: A systematic literature search identified prospective or retrospective studies reporting duration of effect
of onabotulinumtoxinA for the treatment of CD. Inclusion criteria included peer-reviewed, non-review, English-language
articles published between January 1980 and January 2013. A formal meta-analysis using Comprehensive Meta-Analysis
Version 2 was conducted to identify the duration of effect of onabotulinumtoxinA in the treatment of CD; both fixed and
random effects models were performed. Subgroup analyses were performed to identify factors that influenced the duration
of effect of onabotulinumtoxinA.
Results: A total of 18 studies (including >1,900 patients) met the inclusion criteria and were used for the meta-analysis.
The mean duration of effect of onabotulinumtoxinA in CD was found to be 93.2 days (95% CI 91.8-94.6 days) for the
fixed effects model and 95.2 days (95% CI 88.9-101.4 days) for the random effects model. A meta-regression found that
dose of onabotulinumtoxinA and country of origin influenced the duration of effect of onabotulinumtoxinA, whereas
quality score of the article and study type did not. In particular, doses ≥180 Units were associated with longer durations
of effect than doses <180 Units (107-109 days vs. 86-88 days, respectively; p < 0.01). Limitations included pooling studies
that used discrete definitions of duration and had different designs and study quality.
Conclusions: Based on the published literature, the mean duration of effect of onabotulinumtoxinA in CD was
93-95 days (13.2-13.5 weeks). This suggests that, in general, patients with CD treated with onabotulinumtoxinA
should require ~4 treatments per year.
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Cervical dystonia (CD) is a disabling, painful condition in-
volving involuntary movement and posturing of the head
and neck [1]. Botulinum toxin injections have been the
standard of care in the symptomatic management of this
condition since their approval for this indication in
the early 2000s. When injected into skeletal muscle,* Correspondence: gallagher_conor@allergan.com
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reproduction in any medium, provided the orbotulinum toxins act to disrupt neurotransmitter re-
lease at the neuromuscular junction, inducing a transi-
ent weakening of the muscle. Because of the temporary
nature of the effect of botulinum toxins, they need to
be readministered regularly to maintain clinical im-
provement [2,3].
The duration of the clinical benefit produced by a
botulinum toxin is thus an important factor in treat-
ment. A longer duration of effect will reduce thetd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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decreasing the inconvenience of undergoing the injec-
tion treatment and additional co-pay costs, benefiting
physicians in terms of patient scheduling and optimizing
wait times for appointments, and benefiting the health
care system in general in terms of reduced heath care
utilization costs.
The duration of effect of a botulinum toxin can
likely be influenced by multiple factors. In particular,
the dose of a botulinum toxin may affect its dur-
ation, with higher doses generally accepted as produ-
cing a longer clinical benefit, up to a certain point.
As the various commercially available botulinum
toxin products are not interchangeable and differ
from each other in their units of biologic activity, it
is likely that differences may exist in duration of
clinical benefit even if they are used at their ap-
proved unit doses.
Since 2000, onabotulinumtoxinA (BOTOXW; Allergan,
Inc.) has been approved in the US to reduce the severity
of abnormal head position and neck pain in adult pa-
tients with CD [4]. The typical inter-injection interval
employed in clinical practice is 3-4 months [5], with the
label suggesting a minimum inter-injection interval of
3 months [4]. Although some individual studies have
reported the duration of effect of onabotulinumtox-
inA in the treatment of CD [3,6-8], no overall con-
sensus on duration of effect currently exists, and no
prospective trials have been performed specifically to
assess duration. The trial that formed the basis of the
Food and Drug Administration approval of onabotuli-
numtoxinA for the treatment of CD was limited by
the study length and was unable to fully assess dur-
ation of benefit [9]. Furthermore, no dose-ranging
studies have been performed with onabotulinumtox-
inA, so data on whether there is a dose-response
relationship for the duration of effect of onabotuli-
numtoxinA are limited.
Because most payers have minimum reinjection time
limits for reimbursement, an understanding of the dur-
ation of effect of onabotulinumtoxinA in treating CD
and the factors that may influence it, including dose,
can provide clinicians and payers guidance for treat-
ment and coverage decisions, respectively. Thus, we
performed a systematic review and meta-analysis to
evaluate the duration of clinical effect of onabotulinum-
toxinA in patients with CD, and to identify potential
factors that may influence it.
Methods
Literature search
Nine databases (MEDLINEW, EMBASE™, EMBAL, BIOSIS
Previews/RNW, SCISEARCHW, PASCAL, International
Pharmaceutical Abstracts [IPA], Dissertation Abstracts[DISSABS], and HCPlusW) were searched from January
1980 to January 2013 inclusive for published articles
(prospective or retrospective studies) on the treatment
of CD with onabotulinumtoxinA. Medical subject
heading (MeSH) search terms were used to search for
articles on CD: cervical dystonia, torticollis, laterocol-
lis, retrocollis, anterocollis, spasmodic torticollis, wry-
neck. Search terms for onabotulinumtoxinA included:
BOTOXW, botulinum, botulinum neurotoxin A, and
onabotulinumtoxinA. The search results were com-
bined and duplicate articles were removed. Included
articles were peer-reviewed, non-review, English-
language studies of the use of onabotulinumtoxinA
for the treatment of CD published between January
1980 and January 2013.Study selection
Abstracts of all articles were downloaded and manu-
ally reviewed to eliminate articles that did not focus
specifically on the treatment of CD (i.e., false posi-
tives) and did not include the use of onabotulinumtoxinA
for treatment of CD; non-systematic studies (i.e., case re-
ports) were also excluded. The full text of the remaining
articles was then manually reviewed to determine if they
included information on the duration of benefit of
onabotulinumtoxinA in the treatment of CD (Figure 1),
which was the focus of the analysis. The definition of
duration of benefit was as provided by the authors
within each individual article. Data on the duration of
benefit of onabotulinumtoxinA, data needed to calcu-
late an effect size (mean duration of effect and stand-
ard deviation of duration), the number of patients
and dose of onabotulinumtoxinA used in each study,
and the country where each study was performed
were extracted from each published article by WM
and LW. If any of the needed information was not
included in the article, or if any additional data were
needed for the meta-analysis, attempts were made to
contact the corresponding authors.Assessment of data quality
To ascertain the validity of eligible randomized trials,
pairs of reviewers working independently determined
the adequacy of randomization and concealment of
allocation; blinding of patients, health care providers,
data collectors, and outcome assessors; and extent of
loss to follow-up (i.e., proportion of patients in whom
the investigators were not able to ascertain out-
comes). To explore variability in study results (het-
erogeneity), we specified the following hypothesis
before conducting the analysis: that effect size may
differ according to the methodological quality of the
studies.
Figure 1 Flow diagram showing systematic search strategy and selection of articles.
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using a modified version of the 24-item Cho & Bero
instrument [10], which is an accepted method for
evaluating article quality [11-16]. The bulk of the
questions on the instrument are scored as ‘yes’, ‘par-
tial’, or ‘no’ and have values of 2, 1, and 0, respect-
ively; questions may also be scored as ‘not
applicable’ to a particular article, which has a value
of 0. The total score each article can receive ranges
between 0 and 45. The two researchers then com-
pared their scores for each article. Where scoresdiffered by two points or less, an average of the two
scores was used. Where scores differed by greater
than two points, a discussion was held between the
two researchers to assess questions in which the re-
searchers had disagreements. Differences in scoring
were resolved by consensus to produce an agreed-
upon quality score.
Meta-analytic methods
A formal meta-analysis to determine duration of
effect of onabotulinumtoxinA was performed using
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International, Inc., Tampa, FL, USA). A standard ef-
fect size based upon means and standard deviations
was performed on the duration of treatment. Both
fixed effects and random effects models were per-
formed on the data. The Q-statistic for heterogen-
eity, I-squared, and Tau-squared were investigated
to determine whether the overall effect size had sig-
nificant heterogeneity across the fixed and random
effects models. In the presence of significant hetero-
geneity, various article demographics and dosing of
onabotulinumtoxinA were investigated through meta-
regression and subgroup analysis for possible sources of
variation among the published articles. Subgroup analyses
were performed to identify variables that influenced the
duration of effect of onabotulinumtoxinA.Assessment of potential publication bias
We performed several tests to assess for potential publi-
cation bias, including a classic fail-safe N (which is the
number of additional studies that would be required to in-
crease the p value for a meta-analysis to a level of non-
significance [greater than 0.05]), the Begg and Mazumdar
rank correlation, and funnel plots. A funnel plot was used
to determine whether selective publication of small studies
with positive results along with non-publication of small
studies with negative results could have unduly influenced
the outcome of the meta-analysis. Ideally, a funnel plot
should show the studies equally distributed around the
mean effect size and forming a funnel with the smaller
sample size studies near the bottom due to their greater
standard error.Results
Literature search results
The initial literature search identified 2,586 unique articles
on the treatment of CD with botulinum toxins (Figure 1).
After review, 1,562 articles were discarded as they did not
meet the inclusion criteria, and after examining the ab-
stracts of the remaining 1,024 articles, a further 996 arti-
cles were excluded as they did not focus on CD, did not
use onabotulinumtoxinA for the treatment of CD, or were
not systematic studies (i.e., case reports), leaving 28
potentially-relevant articles. All 28 articles were then
reviewed to see if they contained the information needed
for the meta-analysis, including information on the dur-
ation of effect of onabotulinumtoxinA for the treatment of
CD, along with information to calculate an effect size
(mean duration of effect and standard deviation of dur-
ation). Four studies did not contain information on the
duration of effect of onabotulinumtoxinA and were elimi-
nated. Two articles reported data from the same set of pa-
tients as other articles and were eliminated to avoidduplication of data sets. Seven studies did not contain the
necessary information to calculate an effect size for dur-
ation (e.g., means when medians were published, standard
errors, etc.); between contacting authors and examining
internal company study results, missing data for three of
the studies were obtained. Thus, 18 unique studies met
all inclusion criteria and had usable results (Table 1)
[3,6-8,17-30]. From the 18 studies, 19 duration of effect
estimates were obtained because one article contained two
arms of a trial for which independent data could be ex-
tracted. Similarly, three of the 18 studies that contained
duration information did not contain detailed information
on the mean dose of onabotulinumtoxinA that was used
[25,29], but the dose data were obtained from authors
and/or internal company records.
Demographic and meta-analytic results
Publication dates for the 18 chosen studies were between
1990 and 2012. The quality scores for the 18 articles
ranged from 11 to 42. Duration of effect for onabotuli-
numtoxinA across the articles ranged from 64.3 days to
142.9 days (9.2-20.4 weeks).
The fixed effects model produced a mean duration of ef-
fect of 93.2 days (95% CI 91.8-94.6 days), whereas the ran-
dom effects model showed a mean duration of 95.2 days
(95% CI 88.9-101.4 days). The Q-statistic, I-squared, and
Tau-squared were investigated to determine whether the
overall effect size had significant heterogeneity across the
fixed and random effects models. The Q-statistic was 333.7
(p < 0.01), whereas the I-squared and Tau-squared were
94.6 and 176.2 respectively, indicating significant variation
in duration of benefit for onabotulinumtoxinA between
studies and the need to explore moderating variables.
Several demographic variables were chosen to determine
whether they contributed to the significant variability
across the studies. First, article quality score was subjected
to a meta-regression. The slope of the regression line
was –0.09, which was non-significantly different from zero
(p = 0.25), indicating that quality was not a moderating
variable (Figure 2). Second, the mean dose of onabotuli-
numtoxinA was subjected to a meta-regression (n = 18).
The slope of the line was 0.18, which was significantly dif-
ferent from zero (p < 0.01) (Figure 3), indicating that dose
was a significant moderating factor. Based on a visual in-
spection of the figure, there was a clear difference in mean
duration of effect between studies using a mean dose <180
Units and those using a mean dose ≥180 Units, so a dose
of 180 Units was chosen and articles were then dichoto-
mized around this cut-off point. For studies using a mean
dose <180 Units, the mean durations of effect for the fixed
and random effect size models were found to be 87.8 days
(12.5 weeks) and 85.7 days (12.2 weeks), respectively. For
studies using a mean dose ≥180 Units, the mean durations
Table 1 Studies included in meta-analysis






Definition of duration Country
of origin
Mean (±SD) units Mean (±SD)




232 138.9 ± 46.8 94.3 ± 31.4 days Interval between injection
and first visit at which
TWSTRS severity score
reached 80% of baseline
Ex-US
Bihari 2005 [6] Prospective, single-arm,
crossover study
12a 131 64.3 days Time to reach 70%
TWSTRS score
Ex-US
Brashear 2005 [3] Retrospective 172b 241.80-254.07 108.48 days (year 1) Interval between treatments US
Brashear 2000 [25] Retrospective 60 263 15.5 ± 3.4 weeks Interval between visits US
Brashear 1998 [27] Prospective, single-center
study
149c 219.8 ± 63.5 142.9 ± 85.8 days Average time between
treatments
US
Brin 2008 [29] Prospective, open-label,
multicenter study
326 187.0 ± 76.5 110.2 ± 91.8 days Time from treatment
injection to date of next
injection
US/Ex-US
Brockmann 2012 [24] Retrospective 20 175 ± 76 10.7 ± 1.9 weeks Time between last
treatment and first
subjective notice of
reduction of benefit from
the treatment
Ex-US
Camargo 2008 [18] Prospective, single-center
study
85 151.05 ± 52.55 89.1 ± 21.8 days Patient-reported time to
return of symptoms
Ex-US




Jankovic 2003 [19] Prospective, single-center
study
119 223.9 ± 73.0 14.6 ± 5.6 weeks Not specified US
Jankovic 1990 [26] Prospective cohort 205 105.4 ± 33.8 14.0 ± 6.9 weeks Duration of peak effect US
Maia 2010 [20] Retrospective 67 204.79 13.01 weeks Duration which patient
had any benefit from
treatment
Ex-US
Meija 2005 [21] Retrospective 16d 221.2 ± 129.4 15.4 ± 3.4 weeks Not specified US
Mohammadi 2009 [7] Prospective cohort 44 145 ± 44 10 ± 2.4 weeks Not specified Ex-US
Naumann 2002 [8] Prospective, randomized,
double-blind, crossover
study
59 155 ± 51 13.9 ± 2.6 weeks Time to TWSTRS severity
score ≥10 and rotational
score ≥1
Ex-US
68 157 ± 44 13.6 ± 2.4 weeks
Odergren 1998 [22] Prospective, randomized,
double-blind, parallel-
group study
35 152 ± 45 80.7 ± 14.4 days Time to retreatment Ex-US
Quagliato 2010 [30] Prospective, randomized,
double-blind study




Ranoux 2002 [23] Prospective, randomized,
double-blind, crossover
study
51 104.4 ± 20.6 89.1 ± 19 days Interval between day of
treatment and patient-
reported waning of effect
Ex-US
a48 total patients; only 12 had CD. bCase report forms. c156 total patients; 149 had idiopathic CD. d45 total patients; 16 had CD. e24 total patients; 12
received onabotulinumtoxinA.
Abbreviations: NR not reported, onabotA onabotulinumtoxinA, TWSTRS Toronto Western Spasmodic Torticollis Rating Scale.
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107.2 days (15.3 weeks) and 108.8 days (15.5 weeks), re-
spectively. Subgroup analysis showed the duration of effect
in these two groups to be statistically different (p < 0.01).
Results of analyses using doses of 190 and 200 Units as
the cut off were similar, with no change in statistical sig-
nificance (duration was 88.4 and 87.7 days for the fixedand random effects models for studies using a mean
dose <190 or <200 Units, and 106.9 and 108.8 days for
the fixed and random effects models for studies using
mean doses ≥190 or ≥200 Units).
Next, study type (experimental vs. an observational/
retrospective database analysis) was then assessed to see



























Slope = –0.09 
Figure 2 Regression of quality score on mean duration.
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http://www.biomedcentral.com/1471-2377/14/91random effects mean durations of effect were 92.1 days
(13.2 weeks) and 89.5 days (12.8 weeks), respectively, for
experimental studies. For observational and retrospective
database studies, the fixed and random effects mean dura-
tions of effect were 94.2 days (13.5 weeks) and 99.3 days
(14.2 weeks), respectively. These two groups were not sta-
tistically different (p = 0.14). Finally, country of origin of
the study was investigated. Studies conducted in the US

























Mean dose (units) 
Lower duration Higher duration 
Slope = 0.18 
Figure 3 Regression of mean dose on mean duration.world. The fixed and random effects models showed mean
durations of effect for US-based studies of 107.3 days
(15.3 weeks) and 109.6 days (15.7 weeks), respectively,
whereas non-US studies showed mean durations of effect
of 87.2 days (12.5 weeks) and 84.8 days (12.1 weeks) for the
fixed and random effects models, respectively. However, six
of the seven studies with doses ≥180 Units were done in
the US, and only one of the studies with doses <180 Units
were performed in the US, which suggests the country-of-
origin effect is explained by the doses administered.
Assessment of potential publication bias suggested no
bias was present. The classic fail-safe N was 4,941 stud-
ies, and the Begg and Mazumdar rank correlation, which
is interpreted similar to regular correlation coefficients,
was non-significant with a p value of 0.73. The funnel
plot showed that the data points were equally distributed
around the funnel, but as many data points fall outside
the funnel plot (Figure 4), there might not be one effect
being measured. This is not surprising, however, given
the substantial heterogeneity among studies and because
several moderating variables were significant.
Discussion
Botulinum toxins are considered first-line therapy for
the treatment of CD [31] and must be injected on a re-
peat basis; therefore, duration of clinical benefit is a crit-
ically important factor for both physicians and their
patients. Because there is heterogeneity in the published
literature on how duration is reported, and because no
prospective trials have been performed to assess the dur-




















Mean duration (days) 
Figure 4 Funnel plot of standard error by mean duration.
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duration of clinical effect of onabotulinumtoxinA in pa-
tients with CD and potential factors that may influence
it. None of the studies included in our analysis employed
fixed injection intervals or a predefined study duration,
thus enabling a naturalistic assessment of the waning of
the clinical efficacy of onabotulinumtoxinA. In addition,
as no dose-ranging studies have been performed with
onabotulinumtoxinA, dose data were captured to allow
assessment of the dose-duration relationship. The meta-
analytic approach allowed us to weight studies appro-
priately based on their quality, design, and number of
patients.
Botulinum toxins are a unique class of biologic agents
in which a single injection cycle can provide several
months of clinical improvement in symptoms in a var-
iety of different disease states. Understanding the dur-
ation of clinical benefit of botulinum toxins in the
treatment of CD and its impact on health care utilization
are of importance in the contemporary health care envir-
onment. The required frequency of retreatment may in-
fluence treatment or product selection decisions and
have practical implications for patients, physicians, and
payers. This is even more relevant with the current em-
phasis in health care on incorporating patient-centered
outcomes. A longer duration of effect will result in less
frequent reinjection and should thus be associated with
decreased annualized drug costs, decreased health care
utilization and overall treatment costs, as well as im-
proved patient satisfaction. This reduces the burden on
the health care system, on payers and on patients by de-
creasing demands on physician time, which may im-
prove access to care, lower administrative costs, and
result in less inconvenience and less missed time from
work for patients.
Our meta-analysis, which included 18 studies and over
1,900 patients, found that the mean duration of effect of
onabotulinumtoxinA in the treatment of CD was 93-95
days (13.2-13.5 weeks). We also found that higher doses
of onabotulinumtoxinA were associated with a signifi-
cantly longer duration of effect. For doses ≥180 Units,
the mean duration of effect was 15.3 weeks, while the
mean duration of doses below 180 Units was 12.5 weeks.
Dichotomizing by the 180 Unit dose was selected as
practical after a visual inspection of the data distribution,
as there is no statistical mechanism that could be used
to more rigorously determine a dose to use for analysis.
OnabotulinumtoxinA doses ≥180 Units may thus gener-
ally be preferred by patients, physicians, and payers, as
this should reduce inconvenience for patients, increase
patient satisfaction, and lower health resource costs due
to longer duration of clinical benefit. It should be noted
that performing an overall benefit-risk assessment as a
function of dose, including an analysis of safety data,was not performed as it was not the objective of our
analysis. However, our finding that doses ≥180 Units
provide longer duration is also broadly consistent with
the 236 Unit mean dose (range: 198-300 Units) reported
in the CD pivotal phase 3 study of onabotulinumtoxinA
in the treatment of CD, which was deemed to have an
acceptable safety profile [4], and it should also be noted
that patient dosing and injection pattern for CD is indi-
vidualized on a per-patient basis.
In contrast, the published literature on other botulinum
toxin products shows inconsistent dose-duration and
dose-effect relationships in the treatment of CD. For ex-
ample, a trial of incobotulinumtoxinA for the treatment of
CD compared two doses (120 Units and 240 Units) versus
placebo and found no advantage in objective efficacy
or duration of effect with the higher dose [32]. A dose-
ranging study of abobotulinumtoxinA (which examined
the efficacy and safety of doses of 250, 500, and
1,000 Units) found no difference in efficacy between the
500 and 1,000 Unit doses, although both the 500 and 1,000
Unit doses provided better efficacy than the 250 Unit dose.
The authors also observed that mean duration of effect ap-
peared longer in the 1,000 Unit group, but none of the dif-
ferences reached statistical significance; the study was also
fairly short (only 8 weeks) and the measures of duration
were all indirect [33]. Data from two long-term, multicen-
ter, open-label extension studies of abobotulinumtoxinA for
the treatment of CD, which allowed dose adjustment
ranging from 250 to 1,000 Units following a fixed dose of
500 Units in the placebo-controlled trials, also failed to find
a dose-duration effect [34].
Country of origin of the study was also found to affect
the duration of effect of onabotulinumtoxinA. Specific-
ally, the mean duration of effect was found to be longer
for US-based studies than for studies performed outside
the US (15.7 weeks vs. 12.5 weeks, respectively). This is
not entirely surprising as physicians in clinical practice
outside the US tend to use lower doses than those in the
US, and our analysis revealed that higher doses are asso-
ciated with longer duration of effect.
The four main limitations of meta-analysis are 1) com-
bining studies that used different measuring techniques
and/or definitions of variables; 2) combining studies of dif-
ferent designs and subjective quality; 3) publication bias;
and 4) using studies that contain data on the same set
of patients, which is commonly known as the non-
independence of data problem. For this meta-analysis, all
studies used individualized definitions of duration of effect,
some of which were limited by the design of the studies
themselves (i.e., prospective vs. retrospective). For ex-
ample, in the prospective study by Naumann and col-
leagues, duration of effect was defined as the time from
first injection to qualification for a second treatment
(which was defined as a Toronto Western Spasmodic
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score ≥1) [8], whereas in the retrospective study by
Brashear et al., duration of effect was defined as the ‘inter-
val between visits’ [3]. Several studies that cited a mean
duration also failed to clearly specify an exact definition of
‘duration’ [7,20,21]. Differences such as these could have
influenced the overall duration estimate. For the second
limitation (combining studies of different designs and sub-
jective quality), we found that the quality of each article
did not have an effect on the overall effect size measured.
The third potential limitation is publication bias. As de-
scribed above, we performed several tests to assess for
publication bias, including classic fail-safe N, the Begg and
Mazumdar rank correlation, and funnel plots, all of which
suggested that there was no bias. The final limitation of
meta-analyses (non-independence of data) was handled by
carefully inspecting article methodology and patient char-
acteristics for ‘subject data duplication’. Two published
studies that were identified as potential articles to add to
the meta-analysis were eliminated from consideration due
to apparent data duplication [35,36]. Additionally some
large, well-controlled studies such as the ‘ABCD’ trial [37]
were not included in the meta-analysis as they did not con-
tain all of the necessary information for inclusion in the
meta-analysis (i.e., included median instead of mean and/
or did not include a measure to be able to calculate effect
size), and we were unable to obtain these data from the
investigators.
Notwithstanding the potential limitations, the robust-
ness of this analysis is demonstrated by the strict meta-
analytic technique and the large number of studies and
patients included in the analysis. Furthermore, the po-
tential limitations were systematically mitigated by ro-
bust statistical analyses as described above. Lastly, it
should be noted that the results presented here are spe-
cific to onabotulinumtoxinA and cannot be extrapolated
to any other botulinum toxin, as dosing units of onabo-
tulinumtoxinA are not interchangeable with those of any
other botulinum toxin preparation.
Conclusions
This systematic review and meta-analysis demonstrated
that the duration of effect of onabotulinumtoxinA in the
treatment of CD is 93-95 days (13.2-13.5 weeks), with
higher doses associated with a significantly longer dur-
ation of effect. This suggests that, in general, patients re-
ceiving treatment with onabotulinumtoxinA for CD would
be anticipated to require approximately 4 treatments per
year. This information may provide clinicians and payers
guidance for treatment and treatment decisions with
onabotulinumtoxinA.
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